Skip to main content
. 2017 Aug 4;8(40):68208–68220. doi: 10.18632/oncotarget.19919

Figure 3. Sorafenib protects ALL cells from BV6/TNFα-induced necroptosis.

Figure 3

(A–C) FADD-deficient Jurkat cells were treated for 4 hours with 1 μM BV6 and 1 ng/ml TNFα in the presence or absence of indicated concentrations of Sorafenib (A), GSK’872 (B) or Dabrafenib (C). (D) FADD-deficient Jurkat cells were treated for 4 hours with 1 μM BV6 and 1 ng/ml TNFα in the presence or absence of 10 μM Sorafenib, 10 μM GSK’872 or 10 μM Dabrafenib. (E and F) FADD-deficient Jurkat cells were treated for 2 hours with 1 μM BV6 and 1 ng/ml TNFα in the presence or absence of 10 μM Sorafenib, 6 μM GSK’872 or 0.6 μM Dabrafenib. Expression levels of MLKL, phospho-MLKL and cIAP1 were analyzed by Western blotting, expression of GAPDH served as loading control. (G) FADD-deficient Jurkat cells were treated with or without 1 μM BV6 and 1 ng/ml TNFα in the presence or absence of 10 μM Sorafenib for the indicated time points. Cell death was determined by FSC/SSC analysis (A–D) or PI staining (G) and flow cytometry. Mean and SD of at least three experiments performed in triplicate are shown; *P < 0.05; **P < 0.01; ***P < 0.001.